Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby's body temperature—called therapeutic hypothermia—is often used ...

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...

Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The ...

Lowering the body temperature of preterm infants (born at 33 to 35 weeks of pregnancy) with hypoxic ischemic encephalopathy (HIE)-a type of brain damage caused by oxygen loss-offers no benefits over ...

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to ...